Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 7/20 | 0.54 |
| ▸ | GABRP | O00591 | 11/20 | 0.51 |
| ▸ | GABRD | O14764 | 11/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 11/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 11/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 11/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 11/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 11/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 11/20 | 0.51 |
| ▸ | GABRE | P78334 | 11/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 11/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 11/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 11/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 11/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17553241 | 0.86 | GRM4 (0.54) | GRM4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1869134 | 0.86 | GRM4 (0.56) | GRM4TP53CYP3A4MAPTMAPK1 | |
| SCHEMBL19321804 | 0.83 | GRM4 (0.74) | GRM4 | |
| SCHEMBL1870262 | 0.81 | GRM4 (0.69) | GRM4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL19321802 | 0.78 | GRM4 (0.53) | GRM4 | |
| SCHEMBL13519285 | 0.78 | GRM4 (0.53) | GRM4 | |
| SCHEMBL1871791 | 0.75 | GRM4 (0.69) | GRM4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1869462 | 0.71 | GRM4 (0.69) | GRM4GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL21633124 | 0.70 | SPR (0.50) | GRM4MAPT | |
| SCHEMBL21633123 | 0.70 | SPR (0.40) | GRM4GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3696183-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | Prexton Therapeutics SA (CH) | 2020-08-19 | — | — | EP | disclosed |
| EP-3696183-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | Prexton Therapeutics SA (CH) | 2020-08-19 | — | — | EP | disclosed |
| EP-3696182-A1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | Prexton Therapeutics SA (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-20200171042-A1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | PREXTON THERAPEUTICS SA (CH) | 2020-06-04 | — | — | US | disclosed |
| US-20200171042-A1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | PREXTON THERAPEUTICS SA (CH) | 2020-06-04 | — | — | US | disclosed |
| EP-3341380-B1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | PREXTON THERAPEUTICS SA (CH) | 2019-11-13 | — | — | EP | disclosed |
| EP-3341380-B1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | PREXTON THERAPEUTICS SA (CH) | 2019-11-13 | — | — | EP | disclosed |
| US-10442818-B2 | Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | PREXTON THERAPEUTICS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-10442818-B2 | Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | PREXTON THERAPEUTICS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3502115-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | Prexton Therapeutics SA (CH) | 2019-06-26 | — | — | EP | disclosed |
| EP-3341380-A1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | Prexton Therapeutics SA (CH) | 2018-07-04 | — | — | EP | disclosed |
| US-20170253613-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | PREXTON THERAPEUTICS SA (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253613-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | PREXTON THERAPEUTICS SA (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253613-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | PREXTON THERAPEUTICS SA (CH) | 2017-09-07 | — | — | US | disclosed |
| EP-3186257-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | Prexton Therapeutics SA (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2017032874-A1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | PREXTON THERAPEUTICS SA (CH) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016030444-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | PREXTON THERAPEUTICS SA (CH) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016030444-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | PREXTON THERAPEUTICS SA (CH) | 2016-03-03 | — | — | WO | disclosed |
| EP-2493871-A1 | NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051478-A1 | NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253613-A1 | NOVEL CHROMONE OXIME DERIVATIVE AND ITS USE AS ALLOSTERIC MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRM3 | GRM4 4/4885GABRP 116/4885GABRD 236/4885 |
| US-20200171042-A1 | BRAIN-PENETRANT CHROMONE OXIME DERIVATIVE FOR THE THERAPY OF LEVODOPA-INDUCED DYSKINESIA | COMT, PARK7, SLC1A2 | GRM4 48/4885GABRP 1796/4885GABRD 1155/4885 |
| US-10442818-B2 | Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors | GRM1, GRM2, GRM3 | GRM4 4/4885GABRP 120/4885GABRD 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.